Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes.
暂无分享,去创建一个
M. Imamura | N. Hiraga | K. Chayama | T. Fujita | D. Miki | H. Aikata | Y. Kawakami | H. Ochi | E. Murakami | T. Kawaoka | Takuro Uchida | T. Nakahara | G. N. Makokha | Yizhou Zhang | M. Tsuge | Ken Tsushima | M. Kurihara | Y. Izaki | C. N. Hayes | Motonobu Nomura | Naoya Oka | M. Yamashita | K. Shiraishi | Hiromi Abe‐Chayama | O. Sato
[1] P. Marcellin. Viral hepatitis: towards the eradication of HCV and a cure for HBV , 2016, Liver international (Print).
[2] T. Asselah,et al. Viral hepatitis: towards the eradication of HCV and a cure for HBV , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[3] A. Alibrandi,et al. Hepatitis B virus (HBV) induces the expression of interleukin-8 that in turn reduces HBV sensitivity to interferon-alpha. , 2013, Virology.
[4] Yongjung Park,et al. Serum cytokine levels in chronic hepatitis B patients receiving peginterferon alpha-2a therapy. , 2012, Hepatobiliary & pancreatic diseases international : HBPD INT.
[5] J. Long,et al. Exome sequencing generates high quality data in non-target regions , 2012, BMC Genomics.
[6] Alina Macovei,et al. Activation of ERAD Pathway by Human Hepatitis B Virus Modulates Viral and Subviral Particle Production , 2012, PloS one.
[7] M. Imamura,et al. Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice. , 2011, The Journal of infectious diseases.
[8] K. Simon,et al. A Randomized Trial of Peginterferon α-2a With or Without Ribavirin for HBeAg-Negative Chronic Hepatitis B , 2010, The American Journal of Gastroenterology.
[9] Yoshiyuki Suzuki,et al. Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.
[10] H. Nomura,et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.
[11] F. Zoulim,et al. Hepatitis B virus resistance to nucleos(t)ide analogues. , 2009, Gastroenterology.
[12] B. Rollins. Where the Confusion Began: Cloning the First Chemokine Receptors , 2009, The Journal of Immunology.
[13] M. Imamura,et al. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice. , 2008, The Journal of general virology.
[14] J. Van Damme,et al. The role of CXC chemokines and their receptors in cancer. , 2008, Cancer letters.
[15] Yoshiyuki Suzuki,et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. , 2008, Journal of hepatology.
[16] M. Imamura,et al. Successful treatment of an entecavir‐resistant hepatitis B virus variant , 2007, Journal of medical virology.
[17] Angeline Bartholomeusz,et al. Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management , 2007, Hepatology.
[18] M. Imamura,et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon , 2007, FEBS letters.
[19] T. Liang,et al. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. , 2007, Gastroenterology.
[20] P. Borrow,et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage , 2007, The Journal of experimental medicine.
[21] C. Mazzucco,et al. Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present , 2006, Antimicrobial Agents and Chemotherapy.
[22] S. Zeuzem,et al. Patterns of viral decline during PEG‐interferon alpha‐2b therapy in HBeAg‐positive chronic hepatitis B: Relation to treatment response , 2006, Hepatology.
[23] I. Su,et al. Hepatitis B virus pre‐S mutants, endoplasmic reticulum stress and hepatocarcinogenesis , 2006, Cancer science.
[24] H. Lee,et al. Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy , 2006, Hepatology.
[25] M. Katze,et al. Application of functional genomics to the chimeric mouse model of HCV infection: optimization of microarray protocols and genomics analysis , 2006, Virology Journal.
[26] Z. Szallasi,et al. Reliability and reproducibility issues in DNA microarray measurements. , 2006, Trends in genetics : TIG.
[27] M. Imamura,et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus , 2005, Hepatology.
[28] T. Okanoue,et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas , 2005, Gut.
[29] John Quackenbush,et al. Multiple-laboratory comparison of microarray platforms , 2005, Nature Methods.
[30] P. Marcellin,et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.
[31] T. Asahara,et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. , 2004, The American journal of pathology.
[32] P. Angus,et al. Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.
[33] R. Purcell,et al. Genomic analysis of the host response to hepatitis B virus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[34] Yoshiyuki Suzuki,et al. Efficacy of Lamivudine Therapy and Factors Associated with Emergence of Resistance in Chronic Hepatitis B Virus Infection in Japan , 2003, Intervirology.
[35] H. Conjeevaram,et al. Management of chronic hepatitis B. , 2003, Journal of hepatology.
[36] D. Tyrrell,et al. Hepatitis C virus replication in mice with chimeric human livers , 2001, Nature Medicine.
[37] C. Bréchot,et al. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). , 2000, Seminars in cancer biology.
[38] K. Chayama,et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapy , 1998, Hepatology.
[39] M. Buti,et al. Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. , 1998, Journal of hepatology.
[40] F. Su,et al. Hepatitis B virus HBx protein activates transcription factor NF-kappaB by acting on multiple cytoplasmic inhibitors of rel-related proteins , 1996, Journal of virology.
[41] D. Schadendorf,et al. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. , 1993, Journal of immunology.
[42] K. Matsushima,et al. Interleukin-8 and MCAF: novel leukocyte recruitment and activating cytokines. , 1992, Chemical immunology.
[43] T. Tokino,et al. The mode of hepatitis B virus DNA integration in chromosomes of human hepatocellular carcinoma. , 1987, Genes & development.
[44] K. Koike,et al. Multiple integration site of hepatitis B virus DNA in hepatocellular carcinoma and chronic active hepatitis tissues from children , 1987, Journal of virology.
[45] H. Hsu,et al. Diverse virological, histopathological and prognostic implications of seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. , 1986, Journal of hepatology.
[46] F. Schaffner,et al. Electron microscopy and immunoelectronmicroscopy of cytoplasmic hepatitis B antigen in hepatocytes. , 1974, The American journal of pathology.